Faeth Therapeutics

FTH

Capitalización de mercado USD 486 M

I am initiating Faeth Therapeutics with a "Buy" rating following its acquisition, name change, and $200M private placement. Company's lead asset, PIKTOR, targets multi-node PAM pathway alterations in endometrial cancer and HR+/HER2- breast cancer, with key phase 2 and 1b/2 data catalysts ahead. Topline results for PIKTOR in 2nd-line advanced endometrial cancer are expected by year-end 2026, with interim breast cancer data in 2027.

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways, today announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026.“Karen helped shape the scientific thesis this company was built on, and she has been a trusted advisor to Faeth since its founding,” said Anand Parikh, Chairm.

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 6, 2026 at 10:00 AM ET featuring Marcus Goncalves, MD, PhD (NYU Langone Health & Scientific Co-founder, Faeth Therapeutics), who will join company management to discuss the PAM (PI3K/AKT/mTOR) pathway in human can.

Does Faeth Therapeutics, Inc. (FTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences:Wells Fargo 21st Annual Healthcare ConferenceTuesday, September 8, 20261x1 investor meetingsBoston, MACiti Biopharma Back to School SummitWednesday, September 9, 2026Fireside chat at 10:00 a.m. ETNew York, NYCantor G.

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective August 25, 2026, pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment.

The mean of analysts' price targets for Faeth Therapeutics, Inc. (FTH) points to a 72.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of sapanisertib and serabelisib (PIKTOR) with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration and.

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations, as the company prepares for upcoming PIKTOR clinical milestones. Tiwari will lead Faeth's technical operations organization, overseeing chemistry, manufacturing and controls (CMC), and supply chain activities supporting the company's PIKTOR clinical development progr.

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted two new employees options to purchase an aggregate of 11,000 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective August 4, 2026, pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment wit.